id	sid	eid	entity	type
ihlr-21707	1	1	microsoft	ORG
ihlr-21707	2	1	14	CARDINAL
ihlr-21707	2	2	1	CARDINAL
ihlr-21707	2	3	d.	NORP
ihlr-21707	2	4	1	CARDINAL
ihlr-21707	2	5	hatch-waxman	PERSON
ihlr-21707	2	6	2	CARDINAL
ihlr-21707	2	7	obamacare	NORP
ihlr-21707	3	1	ftc v. actavis	ORG
ihlr-21707	3	2	b.	PERSON
ihlr-21707	3	3	1	CARDINAL
ihlr-21707	3	4	detailing e.	PERSON
ihlr-21707	3	5	research & development f.	ORG
ihlr-21707	3	6	medicare	ORG
ihlr-21707	3	7	1	CARDINAL
ihlr-21707	3	8	2	CARDINAL
ihlr-21707	3	9	http://doi.org/10.18060/3911.0033	CARDINAL
ihlr-21707	3	10	1	CARDINAL
ihlr-21707	3	11	2	CARDINAL
ihlr-21707	3	12	vertex pharmaceuticals a.	ORG
ihlr-21707	3	13	1	CARDINAL
ihlr-21707	3	14	2	CARDINAL
ihlr-21707	3	15	the united states	GPE
ihlr-21707	3	16	$2.9 trillion	MONEY
ihlr-21707	3	17	2015	DATE
ihlr-21707	3	18	about 48%	PERCENT
ihlr-21707	3	19	americans	NORP
ihlr-21707	3	20	at least one	CARDINAL
ihlr-21707	4	1	10	CARDINAL
ihlr-21707	4	2	americans	NORP
ihlr-21707	4	3	mayo clinic	ORG
ihlr-21707	4	4	olmsted medical center	ORG
ihlr-21707	4	5	fda	ORG
ihlr-21707	4	6	andas	ORG
ihlr-21707	4	7	1	CARDINAL
ihlr-21707	5	1	hatch-waxman	PERSON
ihlr-21707	5	2	hatch-waxman act--25	ORG
ihlr-21707	5	3	years later	DATE
ihlr-21707	7	1	aca”)(“obamacare	PRODUCT
ihlr-21707	9	1	annual	DATE
ihlr-21707	9	2	annual	DATE
ihlr-21707	10	1	d.	NORP
ihlr-21707	10	2	d.	NORP
ihlr-21707	10	3	research & development	ORG
ihlr-21707	11	1	d.	NORP
ihlr-21707	11	2	annual	DATE
ihlr-21707	11	3	d.	NORP
ihlr-21707	11	4	d.	NORP
ihlr-21707	14	1	ftc	ORG
ihlr-21707	14	2	ftc	ORG
ihlr-21707	14	3	ftc v. actavis a. introduction big pharma	ORG
ihlr-21707	14	4	d.	NORP
ihlr-21707	15	1	federal trade commission	ORG
ihlr-21707	15	2	actavis, inc.	ORG
ihlr-21707	16	1	d.	NORP
ihlr-21707	17	1	d.	NORP
ihlr-21707	17	2	supra b.	PERSON
ihlr-21707	18	1	d. c. generic pharmaceutical	PERSON
ihlr-21707	18	2	dozens	CARDINAL
ihlr-21707	18	3	d.	NORP
ihlr-21707	18	4	d. sorrell	ORG
ihlr-21707	18	5	sorrell v. ims health inc.	ORG
ihlr-21707	20	1	sorrell v. ims health	ORG
ihlr-21707	20	2	d.	NORP
ihlr-21707	21	1	d.	NORP
ihlr-21707	21	2	d.	NORP
ihlr-21707	22	1	2014	DATE
ihlr-21707	22	2	d. supra drug development r&d:	ORG
ihlr-21707	22	3	d.	NORP
ihlr-21707	22	4	supra supra supra supra medicines	PERSON
ihlr-21707	22	5	supra f.	PERSON
ihlr-21707	22	6	medicare	ORG
ihlr-21707	23	1	more than 430	CARDINAL
ihlr-21707	23	2	2015	DATE
ihlr-21707	24	1	$51.2 billion	MONEY
ihlr-21707	24	2	2014	DATE
ihlr-21707	24	3	supra supra supra	PERSON
ihlr-21707	25	1	d.	NORP
ihlr-21707	26	1	first	ORDINAL
ihlr-21707	27	1	supra supra	PERSON
ihlr-21707	28	1	d.	NORP
ihlr-21707	30	1	d.	NORP
ihlr-21707	31	1	d.	NORP
ihlr-21707	33	1	d.	NORP
ihlr-21707	34	1	fda	ORG
ihlr-21707	34	2	d.	NORP
ihlr-21707	34	3	first	ORDINAL
ihlr-21707	35	1	supra b.	PERSON
ihlr-21707	36	1	d.	NORP
ihlr-21707	36	2	d.	NORP
ihlr-21707	37	1	new york	GPE
ihlr-21707	37	2	d.	NORP
ihlr-21707	38	1	fda	ORG
ihlr-21707	39	1	id. ftc	PERSON
ihlr-21707	39	2	d.	NORP
ihlr-21707	39	3	irs	ORG
ihlr-21707	39	4	treasury	ORG
ihlr-21707	39	5	january 2002	DATE
ihlr-21707	40	1	d.	NORP
ihlr-21707	41	1	1	CARDINAL
ihlr-21707	41	2	2	CARDINAL
ihlr-21707	44	1	d.	NORP
ihlr-21707	45	1	d.	NORP
ihlr-21707	47	1	d.	NORP
ihlr-21707	47	2	north america	LOC
ihlr-21707	47	3	http://doi.org/10.1377/hlthaff.24.6.1684 2	PRODUCT
ihlr-21707	47	4	supra supra	PERSON
ihlr-21707	47	5	$5 billion	MONEY
ihlr-21707	48	1	d.	NORP
ihlr-21707	49	1	d.	NORP
ihlr-21707	49	2	supra supra c. example	PERSON
ihlr-21707	49	3	supra a.	PERSON
ihlr-21707	50	1	d.	NORP
ihlr-21707	51	1	d.	NORP
ihlr-21707	52	1	d.	NORP
ihlr-21707	52	2	supra supra	PERSON
ihlr-21707	53	1	d.	NORP
ihlr-21707	54	1	no.	DATE
ihlr-21707	55	1	11081l	DATE
ihlr-21707	57	1	1	CARDINAL
ihlr-21707	58	1	d.	NORP
ihlr-21707	58	2	d.	NORP
ihlr-21707	60	1	d.	NORP
ihlr-21707	60	2	americans	NORP
ihlr-21707	60	3	1	CARDINAL
ihlr-21707	60	4	biopharma, inc.	ORG
ihlr-21707	60	5	ten	CARDINAL